These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25906109)

  • 41. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
    Dugger BN; Clark CM; Serrano G; Mariner M; Bedell BJ; Coleman RE; Doraiswamy PM; Lu M; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Zehntner SP; Carpenter AP; Joshi AD; Mintun MA; Pontecorvo MJ; Skovronsky DM; Sue LI; Beach TG
    J Neuropathol Exp Neurol; 2014 Jan; 73(1):72-80. PubMed ID: 24335535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
    Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
    JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of regional gray matter volume abnormalities in Alzheimer׳s disease and late life depression with hippocampal atrophy using VSRAD analysis: a voxel-based morphometry study.
    Shimoda K; Kimura M; Yokota M; Okubo Y
    Psychiatry Res; 2015 Apr; 232(1):71-5. PubMed ID: 25773003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.
    Shokouhi S; Mckay JW; Baker SL; Kang H; Brill AB; Gwirtsman HE; Riddle WR; Claassen DO; Rogers BP;
    Alzheimers Res Ther; 2016 Jan; 8():2. PubMed ID: 26768154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab.
    Chiao P; Bedell BJ; Avants B; Zijdenbos AP; Grand'Maison M; O'Neill P; O'Gorman J; Chen T; Koeppe R
    J Nucl Med; 2019 Jan; 60(1):100-106. PubMed ID: 29777003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease.
    Dicks E; van der Flier WM; Scheltens P; Barkhof F; Tijms BM;
    Neurobiol Aging; 2020 Oct; 94():71-80. PubMed ID: 32585492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spatial patterns of atrophy, hypometabolism, and amyloid deposition in Alzheimer's disease correspond to dissociable functional brain networks.
    Grothe MJ; Teipel SJ;
    Hum Brain Mapp; 2016 Jan; 37(1):35-53. PubMed ID: 26441321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual-phase
    Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC
    J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score.
    Zukotynski K; Gaudet V; Kuo PH; Adamo S; Goubran M; Scott CJM; Bocti C; Borrie M; Chertkow H; Frayne R; Hsiung R; Laforce R; Noseworthy MD; Prato FS; Sahlas DJ; Smith EE; Sossi V; Thiel A; Soucy JP; Tardif JC; Black SE
    Clin Nucl Med; 2020 Jun; 45(6):427-433. PubMed ID: 32366785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.
    Akhtar RS; Xie SX; Chen YJ; Rick J; Gross RG; Nasrallah IM; Van Deerlin VM; Trojanowski JQ; Chen-Plotkin AS; Hurtig HI; Siderowf AD; Dubroff JG; Weintraub D
    PLoS One; 2017; 12(5):e0177924. PubMed ID: 28542444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Precuneus and Cingulate Cortex Atrophy and Hypometabolism in Patients with Alzheimer's Disease and Mild Cognitive Impairment: MRI and (18)F-FDG PET Quantitative Analysis Using FreeSurfer.
    Bailly M; Destrieux C; Hommet C; Mondon K; Cottier JP; Beaufils E; Vierron E; Vercouillie J; Ibazizene M; Voisin T; Payoux P; Barré L; Camus V; Guilloteau D; Ribeiro MJ
    Biomed Res Int; 2015; 2015():583931. PubMed ID: 26346648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18.
    Devous MD; Joshi AD; Navitsky M; Southekal S; Pontecorvo MJ; Shen H; Lu M; Shankle WR; Seibyl JP; Marek K; Mintun MA
    J Nucl Med; 2018 Jun; 59(6):937-943. PubMed ID: 29284675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of the Semiquantitative Static SUVR Method for
    Ottoy J; Verhaeghe J; Niemantsverdriet E; Wyffels L; Somers C; De Roeck E; Struyfs H; Soetewey F; Deleye S; Van den Bossche T; Van Mossevelde S; Ceyssens S; Versijpt J; Stroobants S; Engelborghs S; Staelens S
    J Nucl Med; 2017 Sep; 58(9):1483-1489. PubMed ID: 28336779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Subjective cognitive decline-related worries modulate the relationship between global amyloid load and gray matter volume in preclinical Alzheimer's disease.
    Wang X; Wang M; Wang X; Zhou F; Jiang J; Liu H; Han Y
    Brain Imaging Behav; 2022 Jun; 16(3):1088-1097. PubMed ID: 34743296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of Haralick texture features in brain [
    Campbell DL; Kang H; Shokouhi S
    Clin Interv Aging; 2017; 12():2077-2086. PubMed ID: 29263656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.
    Teipel S; Heinsen H; Amaro E; Grinberg LT; Krause B; Grothe M;
    Neurobiol Aging; 2014 Mar; 35(3):482-91. PubMed ID: 24176625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.